DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20220412

Clinicoepidemiological study of fixed drug eruption in tertiary care hospital

Pranav H. Ladani, Neela V. Bhuptani, Bharti K. Patel, Sagar R. Bhimani

Abstract


Background: Adverse cutaneous drug reactions pose diagnostic difficulties due to a varied clinical manifestations and broad categories of causative agents. Fixed drug eruptions (FDE) are one of them. Present study aims i) to record various clinical features of FDE, their causative agents and ii) to study the pattern of morbidity in patients with FDE in a tertiary care hospital, Rajkot, Gujarat, India.

Methods: The 88 patients with FDEs attending department of dermatology, venereology and leprosy at PDU govt. medical college and hospital, Rajkot, Gujarat from September 2018 to September 2020 were included after informed consent. After taking thorough history, complete blood count and biochemical tests were done. HIV testing was done in severe reactions with generalised involvement. Appropriate treatment was given with counselling regarding the offending drug for prevention of reaction in future.

Results: The male patients were more affected than female patients with M: F ratio of 1.3:1. The most common age group affected was 21-30 years (22.7%). Antimicrobials were the most common offending drugs (43.2%). None of the patients were HIV reactive in our study. No mortality was reported in our study.

Conclusions: The patterns of FDE and the causative drugs are remarkably different in our study. Knowledge of patterns and the causative agents helps in prevention of same reactions in future in patients.


Keywords


FDEs, Antimicrobials, Adverse cutaneous drug reactions

Full Text:

PDF

References


Breathnach SM. Drug Reactions. In. Tony Burns, Stephen Breathnach, Neil Cox, Christopher Griffiths editor. Rook’s Textbook of dermatology,8th ed. Wiley-Blackwell publications. 2010;4(75):75.1-177.

Mahboob A, Haroon TS. Drugs causing fixed eruptions: a study of 450 cases. Int J Dermatol.1998;37:833-8.

Butler D, Elston D. Fixed Drug Eruptions. Available at: emedicine.medscape.com/article/1336702-overview. Accessed on March 11, 2009.

Mizukawa Y, Shiohara T. Fixed drug eruption: a prototypic disorder mediated by effector memory T cells. Curr Allergy Asthma Rep. 2009;9(1):71-7.

Shiohara T, Mizukawa Y. Fixed drug eruption: a disease mediated by self-inflicted responses of intraepidermal T Cells. Eur J Dermatol. 2007;17:201-8.

Teraki Y, Shiohara T. IFN-gamma-producing effector CD8+ T cells and IL-10-producing regulatory CD4+ T cells in fixed drug eruption. J Allergy Clin Immunol. 2003;112(3):609-15.

Ozkaya-Bayazit E. Specific site involvement in fixed drug eruption. J Am Acad Dermatol. 2003;49(6):1003-7.

Bolognia JL, Jorizzo JL, Rapini RP. Fixed drug eruptions. In: Dermatology. London, England: Mosby; 2003:344-5.

Rook’s Textbook of Dermatology, Ninth Edition. Edited by Christopher Griffiths, Jonathan Barker, Tanya Bleiker, Robert Chalmers and Daniel Creamer, 9th edition. 2016;118:11-4.

Patel RM, Marfatia YS. Clinical study of cutaneous drug eruptions in 200 patients. Indian J Dermatol Venereol Leprol. 2008;74:430.

Singh KK, Shrinivas CR, Krupashankar DS, Naik RPC. Study of thirty-three cases of fixed drug eruption, Indian J Dermatol Venereol Leprol. 1990;56:123-4.

Weedon D. The lichenoid reaction pattern ('interface dermatitis'). Skin Pathology. 2nd ed. London, England: Churchill Livingstone; 2002;42-3.